MA28512B1 - Derive heterocyclique accole, composition medicamenteuse en contenant, et son utilisation medicamenteuse - Google Patents

Derive heterocyclique accole, composition medicamenteuse en contenant, et son utilisation medicamenteuse

Info

Publication number
MA28512B1
MA28512B1 MA29361A MA29361A MA28512B1 MA 28512 B1 MA28512 B1 MA 28512B1 MA 29361 A MA29361 A MA 29361A MA 29361 A MA29361 A MA 29361A MA 28512 B1 MA28512 B1 MA 28512B1
Authority
MA
Morocco
Prior art keywords
accole
drug
containing composition
heterocyclic derivative
heterocyclic
Prior art date
Application number
MA29361A
Other languages
English (en)
Inventor
Nobuhiko Fushimi
Hideki Fujikura
Masayuki Isaji
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of MA28512B1 publication Critical patent/MA28512B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA29361A 2004-03-04 2006-10-02 Derive heterocyclique accole, composition medicamenteuse en contenant, et son utilisation medicamenteuse MA28512B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004061429 2004-03-04

Publications (1)

Publication Number Publication Date
MA28512B1 true MA28512B1 (fr) 2007-04-03

Family

ID=34918063

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29361A MA28512B1 (fr) 2004-03-04 2006-10-02 Derive heterocyclique accole, composition medicamenteuse en contenant, et son utilisation medicamenteuse

Country Status (16)

Country Link
US (1) US7732596B2 (fr)
EP (1) EP1724277A4 (fr)
JP (1) JP5078350B2 (fr)
KR (1) KR101214433B1 (fr)
CN (1) CN1934122B (fr)
AU (1) AU2005219777B2 (fr)
CA (1) CA2557320C (fr)
IL (1) IL177513A (fr)
MA (1) MA28512B1 (fr)
NO (1) NO20064412L (fr)
NZ (1) NZ549219A (fr)
PL (1) PL381247A1 (fr)
RU (1) RU2387663C2 (fr)
TW (1) TW200540167A (fr)
WO (1) WO2005085265A1 (fr)
ZA (1) ZA200606792B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2557801C (fr) 2004-03-16 2013-06-25 Boehringer Ingelheim International Gmbh Derives du benzol substitues par un glucopyranosyle,, medicaments renfermant ces composes, leur utilisation et leur procede de production
TW200635599A (en) 2004-12-16 2006-10-16 Boehringer Ingelheim Int Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
ATE445608T1 (de) 2005-02-23 2009-10-15 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2)
EP1874787B1 (fr) 2005-04-15 2009-12-30 Boehringer Ingelheim International GmbH Derives de glucopyranosyl-substitue (heteroaryloxy-benzyl)-benzene utilises comme inhibiteurs de sglt
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
EP1910390B1 (fr) 2005-07-27 2010-05-19 Boehringer Ingelheim International GmbH Derives de ((hetero)cycloalkylethynyl-benzyl)-benzene glucopyranosyl-substitutes, medicaments contenant ces composes, leur utilisation, et procede pour les produire
DE602006017566D1 (de) 2005-08-30 2010-11-25 Boehringer Ingelheim Pharma Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
ES2358051T3 (es) 2005-09-08 2011-05-05 Boehringer Ingelheim International Gmbh Formas cristalinas de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno, métodos para su preparación y su uso para preparar medicamentos.
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
AU2007216452A1 (en) 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
TWI432446B (zh) 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
TWI403516B (zh) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
EP2072522A4 (fr) * 2006-10-13 2010-01-06 Chugai Pharmaceutical Co Ltd Dérivé de spirocétal de thioglucose et utilisation de celui-ci comme agent thérapeutique pour le diabète
CN100586932C (zh) * 2007-01-26 2010-02-03 中国医学科学院医药生物技术研究所 抗肿瘤化合物及其制备方法
WO2008109591A1 (fr) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Analogues de phlorizine utilisés comme inhibiteurs du co-transporteur 2 du sodium-glucose
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
CL2008003653A1 (es) * 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
AP2728A (en) * 2008-08-28 2013-08-31 Pfizer Dioxa-bicyclo[3.2.1.] octane-2,3,4-triol derivatives
HUE050287T2 (hu) 2009-02-13 2020-11-30 Boehringer Ingelheim Int SGLT2-inhibitort, DPP-IV-inhibitort és adott esetben egy további antidiabetikus hatóanyagot tartalmazó gyógyászati készítmény és alkalmazásai
EP4684831A3 (fr) 2009-02-13 2026-03-11 Boehringer Ingelheim International GmbH Inhibiteur de sglt2 pour améliorer la régulation glycémique
NZ598318A (en) 2009-09-30 2014-02-28 Boehringer Ingelheim Int Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
BR112012007085B8 (pt) 2009-09-30 2021-05-25 Boehringer Ingelheim Int processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
WO2011048148A2 (fr) 2009-10-20 2011-04-28 Novartis Ag Dérivé de glycoside et ses utilisations
DK2496583T3 (en) 2009-11-02 2015-02-02 Pfizer Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES
WO2011070592A2 (fr) 2009-12-09 2011-06-16 Panacea Biotec Ltd. Nouveaux dérivés de sucres
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
CA2832951A1 (fr) 2011-04-14 2012-10-18 Novartis Ag Derives de glycoside et leurs utilisations
WO2013038429A2 (fr) 2011-09-13 2013-03-21 Panacea Biotec Ltd. Nouveaux inhibiteurs de sglt
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (fr) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
HK1215378A1 (zh) 2013-04-18 2016-08-26 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
WO2015043473A1 (fr) * 2013-09-25 2015-04-02 Sunshine Lake Pharma Co., Ltd. Dérivés de glucopyranosyl et leurs utilisations en médecine
AU2017357589B2 (en) 2016-11-10 2023-05-11 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US12144811B2 (en) 2017-11-30 2024-11-19 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin related diseases
CN116283895A (zh) * 2023-01-09 2023-06-23 怀化宝华生物科技有限公司 一种2-[2-(噻吩基)乙基]苯甲酸的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
JPH08502721A (ja) 1992-04-03 1996-03-26 ジ・アップジョン・カンパニー 医薬的に活性な二環式‐複素環アミン
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
ES2218338T3 (es) 2000-04-13 2004-11-16 Pfizer Products Inc. Efecto sinergico de gliburida y milrinona.
JP2002193948A (ja) 2000-10-06 2002-07-10 Sankyo Co Ltd α−置換カルボン酸誘導体を含有する糖尿病治療剤
WO2003000712A1 (fr) * 2001-06-20 2003-01-03 Kissei Pharmaceutical Co., Ltd. Derive heterocyclique azote, composition medicinale contenant ce derive, leur utilisation medicinale et intermediaire associe
JP4115105B2 (ja) * 2001-07-02 2008-07-09 協和醗酵工業株式会社 ピラゾール誘導体
EP1495019B1 (fr) * 2002-04-08 2008-07-02 Council of Scientific and Industrial Research Glucopyranoside, son procede d'isolation, composition pharmaceutique contenant ledit glucopyranoside
TWI254635B (en) * 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
PL1609785T3 (pl) * 2003-03-14 2016-07-29 Astellas Pharma Inc Pochodne c-glikozydowe i ich sole
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
CA2557269C (fr) * 2004-03-04 2012-12-04 Kissei Pharmaceutical Co., Ltd. Derivie heterocyclique fondu; composition medicale contenant ce derive et usage medical

Also Published As

Publication number Publication date
TW200540167A (en) 2005-12-16
EP1724277A1 (fr) 2006-11-22
RU2387663C2 (ru) 2010-04-27
PL381247A1 (pl) 2007-05-14
CN1934122B (zh) 2010-08-04
WO2005085265A1 (fr) 2005-09-15
EP1724277A4 (fr) 2012-05-02
TWI361190B (fr) 2012-04-01
JP5078350B2 (ja) 2012-11-21
US20070197449A1 (en) 2007-08-23
US7732596B2 (en) 2010-06-08
CA2557320C (fr) 2013-02-05
KR101214433B1 (ko) 2012-12-21
AU2005219777A1 (en) 2005-09-15
CA2557320A1 (fr) 2005-09-15
NO20064412L (no) 2006-12-04
IL177513A (en) 2011-11-30
NZ549219A (en) 2010-08-27
RU2006131552A (ru) 2008-03-10
AU2005219777B2 (en) 2011-02-03
IL177513A0 (en) 2006-12-10
HK1099556A1 (zh) 2007-08-17
JPWO2005085265A1 (ja) 2008-01-17
ZA200606792B (en) 2007-12-27
KR20060132737A (ko) 2006-12-21
CN1934122A (zh) 2007-03-21

Similar Documents

Publication Publication Date Title
MA28512B1 (fr) Derive heterocyclique accole, composition medicamenteuse en contenant, et son utilisation medicamenteuse
BRPI0508259A (pt) derivado heterocìclico fundido, composição medicinal contendo o mesmo, e uso medicinal do mesmo
MA28869B1 (fr) Phenylaminothiazoles substitues, et leur utilisation
EP1887008A4 (fr) Composé de thièno-triazolo-diazépine et son utilisation médicinale
EP1731506A4 (fr) Derives de 5-hydroxyindol-3-carboxylate et leur utilisation
NL1025404A1 (nl) Pyrazolo-triazine verbindingen en gebruik daarvan.
EP1971600A4 (fr) Derives d'isoxasole et leur utilisation
DE602005001560D1 (de) Zugangskanüle
NO20082249L (no) Fusert heterocyklisk derivat, medisinsk sammensetning inneholdende samme samt medisinsk bruk derav
EP1762234A4 (fr) Activateur d'ampk
ATE479437T1 (de) Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
EP1826209A4 (fr) Derives de nitromethylene et leur utilisation
DE602005002470D1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
DE602005021959D1 (de) Substituierte diazaspiroä4.5üdecanderivate und der
DE602006013878D1 (de) Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel
ATE423117T1 (de) Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone
EP1719409A4 (fr) Composition insecticide
ATE502035T1 (de) 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
IS8220A (is) Bensímídasólafleiður, blöndur sem innihalda þær, framleiðsla þeirra og notkun
DK1773796T3 (da) Oxopiperidinderivater, fremstilling deraf samt terapeutisk anvendelse deraf
FR2870846B1 (fr) Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
FR2878528B1 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
DE602005020457D1 (de) Master-slave-flip-flop, trigger-flip-flop und zähler
EP1742904A4 (fr) Enaminones substitues, leurs derives et leur utilisation
EP1731609A4 (fr) INHIBITEUR DE L'EXPRESSION DE Rad51, MÉDICAMENT CONTENANT L'INHIBITEUR COMME INGRÉDIENT ACTIF ET UTILISATION DE CELUI-CI